Literature DB >> 9024515

Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia.

V M Aquino1, G R Buchanan, I Tkaczewski, M M Mustafa.   

Abstract

PROBLEM: The safety of early hospital discharge (i.e., before the absolute neutrophil count [ANC] exceeds 500 cell/mm3) of febrile neutropenic children and adolescents with cancer who had experienced prolonged neutropenia (i.e., for more than 7 days) following admission has not been studied. METHOD OF STUDY: Three hundred and thirty nine consecutive admissions of children and adolescents with cancer for management of febrile neutropenia were reviewed. Early discharge criteria included absence of fever for 24 hours prior to discharge, sterile blood cultures for 24 hours, evidence of bone marrow recovery defined as a sustained increase in platelet count and ANC or absolute phagocyte count (APC), and control of local infection if present. Children hospitalized with febrile neutropenia who remained neutropenic for more than 7 days were analyzed to assess their outcomes following discharge it they had met criteria for early hospital discharge.
RESULTS: Thirty-three patients in whom neutropenia had persisted for more than 7 days were discharged before attaining an ANC greater than 500/mm3 when they met the early discharge criteria. Only two children (6%) required readmission for recurrent fever, a rate which was not different from that of patients discharged after a more transient episode of neutropenia (2 of 33 vs. 3 of 121, P = 0.3). Both patients who were readmitted had a source of local infection which worsened despite oral antibiotics. Both patients appeared clinically well at the time of readmission and had sterile cultures during their second hospitalization with resolution of local infection.
CONCLUSION: This study confirms that low-risk criteria used to select children with cancer for discharge before complete resolution of neutropenia can be safely applied to those patients whose neutropenia lasted more than 7 days following admission.

Entities:  

Mesh:

Year:  1997        PMID: 9024515     DOI: 10.1002/(sici)1096-911x(199703)28:3<191::aid-mpo7>3.0.co;2-e

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  7 in total

1.  Feasibility of integrated home/hospital physiotherapeutic support for children with cancer.

Authors:  Christian Savio; Alberto Garaventa; Marina Gremmo; Riccardo Camoriano; Luca Manfredini; Sara Fieramosca; Giorgio Dini; Maurizio Miano
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

2.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

3.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 4.  [Febrile neutropenia: practical aspects].

Authors:  P Harten; B Seyfarth; N Schmitz
Journal:  Med Klin (Munich)       Date:  1998-10-15

5.  Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.

Authors:  M Ponraj; Biswajit Dubashi; B H Harish; S Kayal; S L Cyriac; Jogamaya Pattnaik; K Ranjith; Unni S Pillai; Naresh Jadhav; Kiran K Matta; Jagdeep Singh; Esha Jaffa; Bhanu Prakash
Journal:  Support Care Cancer       Date:  2018-05-17       Impact factor: 3.603

Review 6.  Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.

Authors:  Liat Vidal; Itsik Ben Dor; Mical Paul; Noa Eliakim-Raz; Ellisheva Pokroy; Karla Soares-Weiser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-09

7.  Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer.

Authors:  Anat Stern; Elena Carrara; Roni Bitterman; Dafna Yahav; Leonard Leibovici; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2019-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.